AGP Picks
View all

Prolia and Ranmark market growth tied to osteoporosis and bone cancer demand

Nov. 10, 2026
Prolia and Ranmark market growth tied to osteoporosis and bone cancer demand
By AI, Created 00:00 UTC, Nov 10, 2026, AGP -

The Prolia or Ranmark market is expanding on rising osteoporosis and bone metastasis cases, an aging population and broader use of biologic therapies. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest during the forecast period.

Why it matters: - The Prolia or Ranmark market is linked to two big care needs: osteoporosis and cancer-related bone loss. - Demand for bone treatments is rising as populations age and fracture prevention becomes a bigger priority. - The market also reflects wider adoption of biologics and long-acting injectable therapies.

What happened: - The Business Research Company released a market report on Prolia or Ranmark, a prescription drug containing denosumab. - The report says Prolia or Ranmark has grown over the historical period because of more osteoporosis cases, more bone metastases and an aging global population. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to post the highest growth rate during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Denosumab is a monoclonal antibody that blocks RANKL, a protein involved in bone resorption. - By binding to RANKL, the drug prevents interaction with osteoclasts, the cells that break down bone. - The treatment is intended to increase bone density, strengthen bones and reduce fracture risk. - Prolia or Ranmark is used primarily for osteoporosis and bone metastases in cancer patients. - The report flags rising fracture prevention efforts and increased investment in biologics manufacturing as key forecast-period drivers. - The report also points to more specialty clinics, treatment models tailored to bone health and wider use of long-acting injectable medicines. - Targeted monoclonal antibody therapies are gaining traction in bone health care. - Treatments that preserve bone density over the long term are drawing more attention. - Injectable osteoporosis drugs are being used more widely. - Osteoporosis management is putting more emphasis on treatment adherence and monitoring. - Bone cancer is an additional market driver because denosumab helps inhibit osteoclast activity, reduce fractures and slow bone metastases. - The American Cancer Society reported U.S. new bone and joint cancer cases rose from 3,910 in 2022 to 3,970 in 2023. - The report lists new 2026 additions including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report includes a free sample and full report links: Free sample and Full report.

Between the lines: - The report frames the market as a mix of chronic disease treatment demand and oncology support use. - The emphasis on biologics, specialty clinics and adherence suggests competition is shifting toward delivery models and long-duration therapy management, not just drug volume. - Regional growth expectations point to a mature North American market and a faster-expanding Asia-Pacific opportunity.

What's next: - The report expects continued growth as personalized bone treatment approaches develop. - The market will likely keep benefiting from biologics manufacturing investment and broader use of long-acting injectables. - Clinical care for bone disease is expected to keep shifting toward sustained monitoring and prevention-focused treatment plans. - New report tools and updated forecasting materials suggest the next cycle of market analysis will focus more on segmentation, hotspots and competitive scoring.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.